S. Y. Amy Cheung

Follow

Generating author description...

All published works
Action Title Year Authors
+ Impact of estimating glomerular filtration/creatinine clearance equation on pharmacokinetic simulation: An illustrated example of nivolumab 2023 Thao-Nguyen Pham
Yu-Wei Lin
S. Y. Amy Cheung
+ PDF Chat Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach 2022 Bhargava Kandala
Nele Plock
Akshita Chawla
Anna Largajolli
Seth Robey
Kenny J. Watson
Raj Thatavarti
Sheri Dubey
S. Y. Amy Cheung
Rik de Greef
+ PDF Chat V<sup>2</sup>ACHER: Visualization of complex trial data in pharmacometric analyses with covariates 2021 Jos Lommerse
Nele Plock
S. Y. Amy Cheung
Jeffrey R. Sachs
+ A meta-analysis of tumour response and relapse kinetics based on 34,881 patients: A question of cancer type, treatment and line of treatment 2021 James Yates
S. Y. Amy Cheung
+ PDF Chat Quantifying Drug‐Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model 2019 Chiara Fornari
Lenka Oplustil O’Connor
Carmen Pin
Aaron Smith
James Yates
S. Y. Amy Cheung
Duncan I. Jodrell
Jerome T. Mettetal
Teresa Collins
+ Understanding Hematological Toxicities Using Mathematical Modeling 2018 Chiara Fornari
Lenka Oplustil O’Connor
James Yates
S. Y. Amy Cheung
Duncan I. Jodrell
Jerome T. Mettetal
Teresa Collins
+ PDF Chat Structural identifiability for mathematical pharmacology: models of myelosuppression 2018 Neil D. Evans
S. Y. Amy Cheung
James Yates
+ Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014) 2017 FT. Musuamba
Efthymios Manolis
Nicholas H. G. Holford
S. Y. Amy Cheung
Lena E. Friberg
Kayode Ogungbenro
Martin Posch
JWT Yates
Scott Berry
Neal Thomas
+ PDF Chat Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation 2015 SF Marshall
Rolf Burghaus
Valérie Cosson
S. Y. Amy Cheung
Marylore Chenel
O DellaPasqua
Norbert Frey
Bengt Hamrén
Lutz Harnisch
F Ivanow
+ The design and analysis of parallel experiments to produce structurally identifiable models 2013 S. Y. Amy Cheung
James Yates
Leon Aarons
Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ PDF Chat Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation 2015 SF Marshall
Rolf Burghaus
Valérie Cosson
S. Y. Amy Cheung
Marylore Chenel
O DellaPasqua
Norbert Frey
Bengt Hamrén
Lutz Harnisch
F Ivanow
3
+ A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas 2003 John C. Panetta
Mark N. Kirstein
Amar Gajjar
GLakhsmi Nair
Maryam Fouladi
Clinton F. Stewart
2
+ PDF Chat Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response 2013 Brendan C. Bender
Emilie Schindler
Lena E. Friberg
2
+ PDF Chat Blood Cell Dynamics: Half of a Century of Modelling 2016 Laurent Pujo-Menjouet
2
+ Systems Pharmacology for Drug Discovery and Development: Paradigm Shift or Flash in the Pan? 2013 P. Vicini
Piet H. van der Graaf
2
+ Pharmacometrics: A Multidisciplinary Field to Facilitate Critical Thinking in Drug Development and Translational Research Settings 2008 Jeffrey S. Barrett
Michael J. Fossler
K. David Cadieu
Marc R. Gastonguay
2
+ Model-based drug discovery: implementation and impact 2013 Sandra A. G. Visser
Malin Aurell
Rhys D.O. Jones
Virna Schuck
Ann‐Charlotte Egnell
Sheila Annie Peters
Lena Brynne
James Yates
Rasmus Jansson‐Löfmark
Beesan Tan
2
+ Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models 2011 Martin Bergstrand
Andrew C. Hooker
Johan Wallin
Mats O. Karlsson
2
+ Clinical Trial Simulation: A Review 2010 Nicholas H. G. Holford
Subhrojyoti R.C.
Bart A. Ploeger
2
+ PDF Chat A Review of Mixed‐Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis 2014 Benjamin Ribba
Nicholas H. G. Holford
Paolo Magni
Iñaki F. Trocóniz
Ivelina Gueorguieva
Pascal Girard
CĂ©line Sarr
Moran Elishmereni
Charlotte Kloft
Lena E. Friberg
2
+ Clinical trial simulation in drug development. 2000 Peter L. Bonate
2
+ Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications 2005 Venkatesh Atul Bhattaram
Brian Booth
Roshni Ramchandani
B. Nhi Beasley
Yaning Wang
Veneeta Tandon
John Duan
Raman Baweja
Patrick Marroum
Ramana Uppoor
2
+ Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials 2007 Björn Bornkamp
Frank Bretz
Alex Dmitrienko
Greg Enas
Brenda Gaydos
Chyi‐Hung Hsu
Franz König
Michael Krams
Qing Liu
Beat Neuenschwander
2
+ PDF Chat V<sup>2</sup>ACHER: Visualization of complex trial data in pharmacometric analyses with covariates 2021 Jos Lommerse
Nele Plock
S. Y. Amy Cheung
Jeffrey R. Sachs
2
+ PDF Chat Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development 2015 RV Overgaard
SH Ingwersen
CW TornĂže
2
+ Simulation of Clinical Trials 2000 Nicholas H. G. Holford
H. C. Kimko
Jonathan P. R. Monteleone
Carl C. Peck
2
+ Simulation for Designing Clinical Trials 2002 Hui C. Kimko
Stephen B. Duffull
2
+ PDF Chat Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling 2010 Philippe Jacqmin
Lynn McFadyen
Janet R. Wade
1
+ Impact of Modeling and Simulation: Myth or Fact? 2014 Sandy Allerheiligen
1
+ PDF Chat Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors 1999 Jennifer A. Hoeting
David Madigan
Adrian E. Raftery
Chris Volinsky
1
+ PDF Chat Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development 2012 DR Mould
Richard N. Upton
1
+ PDF Chat Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R 2008 Emmanuelle Comets
Karl Brendel
France Mentré
1
+ Randomized concentration-controlled trials: Motivations, use, and limitations 2003 Holger Kraiczi
1
+ Model Selection: An Integral Part of Inference 1997 S. T. Buckland
Kenneth P. Burnham
Nicole H. Augustin
1
+ Applying modeling and simulation to improve the design of a clinical efficacy trial 1999 Madeleine S. Gastonguay
Helen S. Pentikis
Maurice Alexander
Lorraine Lee
1
+ PDF Chat Models for Disease Progression: New Approaches and Uses 2012 Diane R. Mould
1
+ Pharmacometrics : the science of quantitative pharmacology 2007 Ene Ette
Paul J. Williams
1
+ PDF Chat Dose Finding – A Challenge in Statistics 2008 Frank Bretz
Jason C. Hsu
José Paulo Pinheiro
Yi Liu
1
+ The Use of Population Pharmacokinetics in Drug Development 1996 Samuel VoĆŸeh
Jean‐Louis Steimer
Malcolm Rowland
P. L. Morselli
France Mentré
L. P. Balant
Leon Aarons
1
+ Compound D- and D s -Optimum Designs for Determining the Order of a Chemical Reaction 1997 Anthony C. Atkinson
Barbara Bogacka
1
+ PDF Chat An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models 2013 Vittal Shivva
Julia Korell
Ian G. Tucker
Stephen B. Duffull
1
+ Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation 2005 Jenny Y. Chien
Stuart Friedrich
Michael Heathman
Dinesh P. de Alwis
Vikram Sinha
1
+ Computer simulation of a clinical trial as an aid to teaching the concept of statistical significance 1986 John M. Bland
1
+ Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials 2014 René Bruno
François Mercier
Laurent Claret
1
+ Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development 2000 Ronald Gieschke
JL Steimer
1
+ Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. 1992 Carl C. Peck
William H. Barr
Leslie Z. Benet
Jerry M. Collins
Robert E. Desjardins
Daniel E. Furst
John G. Harter
Gerhard Levy
Thomas M. Ludden
John H. Rodman
1
+ Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer 2011 Nicolas Frances
Laurent Claret
René Bruno
Athanassios Iliadis
1
+ PDF Chat Modeling and Simulation at the Interface of Nonclinical and Early Clinical Drug Development 2013 Sandra A. G. Visser
Efthymios Manolis
Meindert Danhof
Thomas Kerbusch
1
+ Clinical Pharmacokinetics in the Drug Regulatory Process 1990 Tomas Salmonson
Anders Rane
1
+ PDF Chat Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods 2013 DR Mould
Richard N. Upton
1
+ PDF Chat Testing and estimation in flexible group sequential designs with adaptive treatment selection 2005 Martin Posch
Franz Koenig
Michael Branson
Werner Brannath
Cornelia Dunger‐Baldauf
PĂ©ter Bauer
1
+ PDF Chat Clinical Trial Simulation in Drug Development 2004 Pascal Girard
Michel Cucherat
David Guez
Jean‐Pierre Boissel
Michel Cucherat
Sylvain Durrleman
Pascal Girard
David Guez
R. Koen
Christian Laveille
1
+ PDF Chat Stability analysis of multi-compartment models for cell production systems 2011 Yukihiko Nakata
Philipp Getto
Anna Marciniak‐Czochra
TomĂĄs AlarcĂłn
1
+ Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop 2014 Klaus Romero
Vikram Sinha
Sandra R. B. Allerheiligen
Meindert Danhof
JosĂ© Cirı́aco Pinheiro
Naomi L. Kruhlak
Yaning Wang
Sue-Jane Wang
J M Sauer
Jean‐François Marier
1
+ Model-Based Meta-Analysis for Comparative Efficacy and Safety: Application in Drug Development and Beyond 2011 Jaap W. Mandema
MA Gibbs
Rebecca A. Boyd
Daisuke Wada
Marc Pfister
1
+ Utilisation of Pharmacokinetic- Pharmacodynamic Modelling and Simulation in Regulatory Decision-Making 2001 Jogarao Gobburu
Patrick Marroum
1
+ PDF Chat Implementation of Quantitative and Systems Pharmacology in Large Pharma 2014 Sandra A. G. Visser
Dinesh P. de Alwis
Thomas Kerbusch
Julie A. Stone
Sandra R. B. Allerheiligen
1
+ PDF Chat Modeling and Simulation as a Tool to Bridge Efficacy and Safety Data in Special Populations 2013 Lutz Harnisch
Terry Shepard
Guillaume Pons
Oscar Della Pasqua
1
+ The design and analysis of parallel experiments to produce structurally identifiable models 2013 S. Y. Amy Cheung
James Yates
Leon Aarons
1
+ Characterization of dose-response for count data using a generalized MCP-Mod approach in an adaptive dose-ranging trial 2015 François Mercier
Bjoern Bornkamp
David Ohlssen
Erik Wallstroem
1